prof. dr. A.D.R. (Alwin) Huitema

prof. dr. A.D.R. (Alwin) Huitema

Full Professor
prof. dr. A.D.R. (Alwin) Huitema
  • Clinical Pharmacy

Research Programs

Strategic Program Cancer

Side Activities

2002 - 2021 : Member of the Medical Ethical Committee of Netherlands Cancer Institute

2003 - : Involved in many early clinical trials of novel anticancer agents (not further specified, revenues for Netherlands Cancer Institute, Princess Máxima Center or University Medical Center Utrecht)

2016 - 2018: Member of scientific councel "Stichting Kinderen Kankervrij (KiKa)"

2017 - 2021 : Member of the working group Oncology & Hematology of "Horizonscan geneesmiddelen", ZorgInstituut Nederland

2018 - 2023: Board member of Dutch Society of Clinical Pharmacology & Biopharmaceutics

2021 - 2022: Member of the external evaluation committee of 10 year program "Goed Geneesmiddelen Gebruik"

2023 - : Member of the working party for the "Kennisagenda 2.0" of the Dutch Association of Hospital Pharmacists

2023 -: Member of the "Concilium" of the Dutch Association of Hospital Pharmacists

Fellowship and Awards

2015 Galenus research prize

2014 Huizinga penning of the Dutch Association of Hospital Pharmacists

Research Output (275)

Ion suppression, reduced long-term robustness and leakage current of the spray voltage during the ionization of trichloroacetic acid; a case study with a methylmalonic acid assay

Punt Arjen M., van der Elst Kim C.M., Huitema Alwin D.R., Lentjes Eef G.W.M. 30 May 2023, In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 1224

WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer:A biomarker-enriched phase II study

Embaby Alaa, Kutzera Joachim, Geenen Jill J, Pluim Dick, Hofland Ingrid, Sanders Joyce, Lopez-Yurda Marta, Beijnen Jos H, Huitema Alwin D R, Witteveen Petronella O, Steeghs Neeltje, van Haaften Gijs, van Vugt Marcel A T M, de Ridder Jeroen, Opdam Frans L 24 May 2023, In: Gynecologic Oncology. 174 , p. 239-246 8 p.

Optimization of a Quantitative Anti-Drug Antibodies against Infliximab Assay with the Liquid Chromatography-Tandem Mass Spectrometry:A Method Validation Study and Future Perspectives

Smeijsters Erin H, van der Elst Kim C M, Visch Amy, Göbel Camiel, Loeff Floris C, Rispens Theo, Huitema Alwin D R, van Luin Matthijs, El Amrani Mohsin 12 May 2023, In: Pharmaceutics. 15

Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model

't Hart E, Bianco J, Bruin M A C, Derieppe M, Besse H C, Berkhout K, Chin Joe Kie L A, Su Y, Hoving E W, Huitema A D R, Ries M G, van Vuurden D G 5 Apr 2023, In: Journal of controlled release : official journal of the Controlled Release Society. 357 , p. 287-298 12 p.

Clinical development of WEE1 inhibitors in gynecological cancers:A systematic review

Schutte Tim, Embaby Alaa, Steeghs Neeltje, van der Mierden Stevie, van Driel Willemien, Rijlaarsdam Martin, Huitema Alwin, Opdam Frans Apr 2023, In: Cancer Treatment Reviews. 115 15 p.

A sensitive liquid chromatographic-mass spectrometry method for the quantification of vincristine in whole blood collected with volumetric absorptive microsampling

van der Heijden Lisa T., Uittenboogaard Aniek, Nijstad A. Laura, Gebretensae Abadi, Kaspers Gertjan J.L., Beijnen Jos H., Huitema Alwin D.R., Rosing Hilde 20 Feb 2023, In: Journal of Pharmaceutical and Biomedical Analysis. 225

A physiologically based pharmacokinetic model for [<sup>68</sup>Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients

Siebinga Hinke, de Wit-van der Veen Berlinda J., Beijnen Jos H., Dorlo Thomas P.C., Huitema Alwin D.R., Hendrikx Jeroen J.M.A. 3 Feb 2023, In: EJNMMI Research. 13 16 p.

Time above threshold plasma concentrations as pharmacokinetic parameter in the comparison of oral and intravenous docetaxel treatment of breast cancer tumors

Van Eijk Maarten, Beijnen Jos H., Huitema Alwin D.R. 1 Feb 2023, In: Anti-Cancer Drugs. 34 , p. 281-289 9 p.

Prediction of the pharmacokinetics of pemetrexed with a low test dose:A proof-of-concept study

Boosman René J., de Rouw Nikki, Huitema Alwin D.R., Burgers Jacobus A., ter Heine Rob Feb 2023, In: British Journal of Clinical Pharmacology. 89 , p. 699-704 6 p.

Prediction of Busulfan Clearance by Predose Plasma Metabolomic Profiling

McCune Jeannine S., Navarro Sandi L., Baker K. Scott, Risler Linda J., Phillips Brian R., Randolph Timothy W., Shireman Laura, Schoch H. Gary, Deeg H. Joachim, Zhang Yuzheng, Men Alex, Maton Loes, Huitema Alwin D.R. Feb 2023, In: Clinical Pharmacology and Therapeutics. 113 , p. 370-379 10 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet